⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629472 | 0.79 | — | — | |
| Vpn-4090Ce SCHEMBL259901 | 0.70 | MEN1 (0.32) | — | |
| Laromustine SCHEMBL2416976 | 0.69 | CA12 (0.30) | — | |
| SCHEMBL11514942 | 0.64 | MAPK1 (0.30) | — | |
| SCHEMBL819369 | 0.62 | CA2 (0.39) | — | |
| SCHEMBL6690514 | 0.62 | EGFR (0.30) | — | |
| SCHEMBL995245 | 0.61 | MEN1 (0.39) | — | |
| SCHEMBL4588092 | 0.59 | — | — | |
| SCHEMBL13895324 | 0.58 | KDM4E (0.37) | — | |
| SCHEMBL2755808 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111534022-A | Prevent soft selfreparing PVC membrane of static | 鲍仲敏 | 2020-08-14 | — | — | CN | claimed |
| CN-111534022-A | Prevent soft selfreparing PVC membrane of static | 鲍仲敏 | 2020-08-14 | — | — | CN | disclosed |
| EP-1804816-A4 | COMBINATION THERAPY COMPRISING CLORETAZINE(TM) | VION PHARMACEUTICALS INC (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-101014353-A | Combination therapy comprising cloretazine(tm) | VION PHARMACEUTICALS INC (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1804816-A2 | COMBINATION THERAPY COMPRISING CLORETAZINE(TM) | Vion Pharmaceuticals, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2005094282-A2 | COMBINATION THERAPY COMPRISING CLORETAZINETM | VION PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |